Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
15 Septiembre 2023 - 6:00AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
September
2023
Commission
File Number: 001-41386
OKYO
Pharma LTD
(Exact
Name of Registrant as Specified in Its Charter)
9th
Floor
107
Cheapside
London
EC2V
6DN
(Address
of registrant’s principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION
CONTAINED IN THIS REPORT ON FORM 6-K
On
September 15, 2023, OKYO Pharma LTD (the “Company”) issued this 6K announcing, the closing of its previously announced
Company best efforts registered direct offering of 2,666,670 ordinary shares at an offering price of $1.50 per ordinary share conducted
without an underwriter or placement agent to individuals and institutions. The gross proceeds to OKYO from the offering, before deducting
estimated offering expenses payable by OKYO, were $4.0 million., a copy of which is furnished as Exhibit 99.1
The
Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being
furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise
subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under
the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly
set forth by specific reference in such a filing.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
OKYO Pharma LTD |
|
|
|
Date: September 15, 2023 |
By: |
/s/ Keeren
Shah |
|
Name: |
Keeren Shah |
|
Title: |
Chief Financial Officer |
EXHIBIT
INDEX
Exhibit 99.1
OKYO
Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares
London
and New York, NY – September 15, 2023 – OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”),
an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED”), today announced
the closing of its previously announced Company best efforts registered direct offering of 2,666,670
ordinary shares at an offering price of $1.50 per ordinary share conducted without an underwriter or placement agent to individuals
and institutions. The gross proceeds to OKYO from the offering, before deducting estimated offering expenses payable by OKYO, were $4.0
million.
OKYO
intends to use the net proceeds from the offering primarily for clinical development of the Company’s product candidates, general
corporate purposes and working capital.
The
securities described above are being offered and sold pursuant to a shelf registration statement on Form F-3 (File No. 333-272516), including
a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on June 8, 2023, and declared effective
on June 14, 2023. The offering is being made only by means of a prospectus supplement and the accompanying
base prospectus, as may be further supplemented by any free writing prospectus and/or pricing supplement that the Company may file with
the SEC. The final prospectus supplement related to the offering has been filed with the SEC and is available on the SEC website.
This
press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities
in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under
the securities laws of such state or jurisdiction.
About
OKYO Pharma
OKYO
Pharma Limited (Nasdaq: OKYO) is a life sciences company, focusing on the discovery and development of novel molecules to treat inflammatory
dry eye diseases and chronic pain.
Forward-Looking
Statements
Statements
in this press release may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933,
as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties
that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements.
These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates,
and projections about its industry; its beliefs; and assumptions. Words such as ‘anticipates,’ ‘expects,’ ‘intends,’
‘plans,’ ‘believes,’ ‘seeks,’ ‘estimates,’ and similar expressions are intended to identify
forward-looking statements. These forward-looking statements reflect the current beliefs and expectations
of management and include statements regarding the closing of the offering and the registered direct offering. These statements
are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which
are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed
or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place
undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. Forward-looking
statements are subject to risks and uncertainties that may cause the Company’s actual activities or results to differ materially
from those indicated or implied by any forward-looking statement, including, without limitation, due to risks disclosed in the section
titled “Risk Factors” included in the final prospectus supplement filed with the SEC, and risks disclosed in other
documents OKYO files from time to time with the SEC. The forward-looking statements made in this announcement relate only to events
as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates
to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement
except as required by law or by any appropriate regulatory authority.
Enquiries:
OKYO
Pharma Limited |
Gary
S. Jacob, Chief Executive Officer |
+44
(0)20 7495 2379 |
Investor
Relations |
Paul
Spencer |
+44
(0)20 7495 2379
|
OKYO Pharma (NASDAQ:OKYO)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
OKYO Pharma (NASDAQ:OKYO)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024